Rockwell Medical (RMTI) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Share on StockTwits

Rockwell Medical (NASDAQ:RMTI) issued its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02), Morningstar.com reports. Rockwell Medical had a negative net margin of 53.40% and a negative return on equity of 117.31%. The company had revenue of $16.85 million during the quarter, compared to analysts’ expectations of $16.10 million.

NASDAQ RMTI traded down $0.05 during mid-day trading on Friday, reaching $4.98. 700 shares of the stock were exchanged, compared to its average volume of 269,842. Rockwell Medical has a 1-year low of $2.19 and a 1-year high of $6.92. The firm has a market cap of $289.45 million, a P/E ratio of -9.77 and a beta of 2.09.

A number of research analysts have issued reports on the stock. ValuEngine cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Zacks Investment Research upgraded shares of Rockwell Medical from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Thursday, November 15th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of Rockwell Medical by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 539,787 shares of the company’s stock valued at $1,219,000 after purchasing an additional 57,340 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Rockwell Medical by 23.2% in the 4th quarter. Jane Street Group LLC now owns 36,472 shares of the company’s stock valued at $82,000 after purchasing an additional 6,870 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Rockwell Medical by 337.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 133,583 shares of the company’s stock valued at $302,000 after purchasing an additional 103,028 shares during the last quarter. Rehmann Capital Advisory Group boosted its holdings in shares of Rockwell Medical by 20.9% in the 4th quarter. Rehmann Capital Advisory Group now owns 72,755 shares of the company’s stock valued at $164,000 after purchasing an additional 12,563 shares during the last quarter. Finally, Provident Investment Management Inc. boosted its holdings in shares of Rockwell Medical by 50.0% in the 4th quarter. Provident Investment Management Inc. now owns 45,000 shares of the company’s stock valued at $102,000 after purchasing an additional 15,000 shares during the last quarter. Hedge funds and other institutional investors own 19.02% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4223068/rockwell-medical-rmti-posts-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

Rockwell Medical Company Profile

Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.

Featured Story: How to find the components of the quick ratio

Earnings History for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Labrador Technologies  Sets New 52-Week Low at $0.01
Labrador Technologies Sets New 52-Week Low at $0.01
TC Pipelines  Reaches New 1-Year High at $37.45
TC Pipelines Reaches New 1-Year High at $37.45
Quantum   Trading 34.2% Lower  Over Last Week
Quantum Trading 34.2% Lower Over Last Week
Saratoga Investment Corp  Receives Consensus Rating of “Buy” from Brokerages
Saratoga Investment Corp Receives Consensus Rating of “Buy” from Brokerages
BlitzPredict Price Tops $0.0007 on Major Exchanges
BlitzPredict Price Tops $0.0007 on Major Exchanges
Zilliqa Reaches Market Cap of $169.68 Million
Zilliqa Reaches Market Cap of $169.68 Million


© 2006-2019 Ticker Report